|Articles|May 1, 2001
- Pharmaceutical Executive-05-01-2001
- Volume 0
- Issue 0
Friends of Complexity
Author(s)Wayne Koberstein
Pharmaceutical executives should study their own scientists. They construct clever tools to explore convoluted phenomena. They are the true friends of complexity.
Advertisement
Articles in this issue
almost 25 years ago
Policy: Task Mastersalmost 25 years ago
Pharmacia's Carrie Cox: HBA Woman of the Yearalmost 25 years ago
Under Federal Firealmost 25 years ago
Task Force: Enter the Fixersalmost 25 years ago
The Next Y2Kalmost 25 years ago
Political ScienceNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review
2
Vinay Prasad Out at CBER for Second Time in Under a Year
3
Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial
4
Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals
5